-
Most Recent
Search Results
240 results for abb
Is AbbVie Stock An Undiscovered Cannabis Play Waiting For Some Attention?
AbbVie stock’s been fairly awful lately as its core drug is showing signs of slowing down. Yet ABBV stock should not be ignored since there’s…
AbbVie Stock Is More Than a Great Dividend Payer
It’s fine if you want to hold ABBV stock for the dividend payouts, but there are also other reasons to own it.
3 Big Chart Stocks for Friday: Oracle Corporation (ORCL), salesforce.com, inc. (CRM) and AbbVie Inc (ABBV)
Salesforce (CRM), AbbVie (ABBV) and Oracle (ORCL) have all increased in volatility selling this week, as have broken key technical support.
Buy AbbVie Stock as the Drugmaker Diversifies Its Pipeline
With a major acquisition in the works, ABBV stock isn’t just a dividend king, but a rapidly-diversifying juggernaut.
AbbVie-Allergan Deal: AGN Stock Soars on $63 Billion Buyout
News of an AbbVie-Allergan deal has AGG stock heading higher on Tuesday with plans for the former company to acquire the latter.
AI’s $700 Billion Question
Alphabet says AI demand is outrunning supply … AWS logs its fastest growth in four years … Meta beats but pulls back 10% … and…
High-Level Measures for Earnings Momentum Keep AbbVie (ABBV) a Strong Buy
Currently, AbbVie Inc (NYSE:ABBV) has a Strong Buy using Louis Navellier’s methodology for investing and his Portfolio Grader stock evaluator. ABBV has recently seen its…
AbbVie Stock’s Healthy Yield Makes it a High-Conviction Holding
Between the dividend payouts and the potential price appreciation, ABBV stock could be a pharma-market winner in 2022.
AbbVie (ABBV) a Buy on Strong Quant Score
Currently, AbbVie Inc (NYSE:ABBV) has a Buy using the methodology of Louis Navellier for investing and his Portfolio Grader stock evaluator. ABBV has maintained this…
The AbbVie Buyout is Not a Sure Thing for Allergan Stock Investors
The coronavirus has completely changed the narrative on AbbVie’s buyout of AGN. Allergan stock holders banking on it should reconsider.
Why You Can Buy AbbVie At a Massive Discount
ABBV stock does not fully reflect the deep pipeline of drugs under development and the billions in future sales from two key drugs.
Monday’s Vital Data: Apple Inc. (AAPL), Netflix Inc. (NFLX) and AbbVie Inc. (ABBV)
A look at what has sparked some major options activity in Apple Inc. (AAPL), Netflix Inc. (NFLX) and AbbVie Inc (ABBV).
Why AbbVie Inc (ABBV), Greif, Inc. (GEF) and Embraer SA (ADR) (ERJ) Are 3 of Today’s Worst Stocks
AbbVie (ABBV), Greif (GEF) and Embraer SA (ERJ) were at the bottom of the barrel on Thursday. This is what investors need to know about…
AbbVie Is Worth 28% More Based on Impressive Dividends
AbbVie is still cheap despite its gains and has an attractive prospective yield. ABBV stock trades for less than 8x next year’s earnings with a…
AbbVie (ABBV) a Buy on Healthy Earnings Momentum
AbbVie Inc (NYSE:ABBV) is ranked as a Buy using the approach to investing of Louis Navellier and his Portfolio Grader stock evaluator. This represents no…
Why AbbVie Inc (ABBV), GrubHub Inc (GRUB) and LendingClub Corp (LC) Are 3 of Today’s Worst Stocks
AbbVie (ABBV), GrubHub (GRUB) and LendingClub (LC) didn’t even have a prayer of making bullish progress on Tuesday.
Exceptional Metrics for Sales Growth Keep AbbVie (ABBV) a Strong Buy at recent price of $116.34
AbbVie Inc’s Strong Buy recommendation is the outcome of an analytical process that is proprietary and produced results that were above average in 5 areas:…
AbbVie (ABBV) a Buy on Robust Quant Score
AbbVie Inc (NYSE:ABBV) is a $147.1 billion in market value member of the Biotechnology GICS industry group where the stock’s current Portfolio Grader score places…
Does Recent Weakness in AbbVie Stock Make It a Buy? 3 Pros, 3 Cons
ABBV stock offers huge reward with its 5.3% dividend yield, and also huge risk with Humira’s generic competition. What’s the right play?
AbbVie Remains One of the Safest Pharma Investments You Can Make
The pharmaceutical market has its ups and downs, but that doesn’t mean every investment is risky as ABBV stock is a reasonably safe bet.
This Pharmaceutical Company is Oversold and Starting to Recover
This morning, I am recommending a bullish trade on AbbVie, Inc. (NYSE:ABBV), the biopharmaceutical company.
Which Abbott Is the One to Own Post-Split?
Both offer good prospects, but if you can choose just one, AbbVie — which is the device and diagnostics side — looks a tad more…
Ignore the Coronavirus Catalyst for ABBV Stock
Without a coronavirus treatment, the medical community is experimenting with repurposed drugs. In this regard, the present crisis may benefit ABBV stock. Still, AbbVie has…
5 – 10 of 240 results
